DK2398476T3 - Policosanolnanopartikler - Google Patents

Policosanolnanopartikler Download PDF

Info

Publication number
DK2398476T3
DK2398476T3 DK10744101.6T DK10744101T DK2398476T3 DK 2398476 T3 DK2398476 T3 DK 2398476T3 DK 10744101 T DK10744101 T DK 10744101T DK 2398476 T3 DK2398476 T3 DK 2398476T3
Authority
DK
Denmark
Prior art keywords
policosanol
levels
vol
octacosanol
nanoparticles
Prior art date
Application number
DK10744101.6T
Other languages
English (en)
Inventor
Palayakotai R Raghavan
Original Assignee
Nanorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2398476(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nanorx Inc filed Critical Nanorx Inc
Application granted granted Critical
Publication of DK2398476T3 publication Critical patent/DK2398476T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (1)

10. Ikke-terapeutisk anvendelse af den farmaceutiske formulering ifølge krav 7 til reduktion af taljemål hos et individ.
DK10744101.6T 2009-02-23 2010-01-21 Policosanolnanopartikler DK2398476T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15471209P 2009-02-23 2009-02-23
PCT/US2010/021684 WO2010096231A1 (en) 2009-02-23 2010-01-21 Policosanol nanoparticles

Publications (1)

Publication Number Publication Date
DK2398476T3 true DK2398476T3 (da) 2018-04-16

Family

ID=42631178

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10744101.6T DK2398476T3 (da) 2009-02-23 2010-01-21 Policosanolnanopartikler

Country Status (12)

Country Link
US (1) US8722093B2 (da)
EP (1) EP2398476B1 (da)
JP (1) JP5711671B2 (da)
CN (1) CN102292088B (da)
AR (1) AR075686A1 (da)
AU (1) AU2010216337B2 (da)
CA (1) CA2788777C (da)
CL (1) CL2010000063A1 (da)
DK (1) DK2398476T3 (da)
ES (1) ES2663299T3 (da)
TW (1) TW201038287A (da)
WO (1) WO2010096231A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247322B (zh) * 2011-07-13 2013-01-16 广东省食品工业研究所 一种二十八碳醇微乳液及其制备方法
CN105188687B (zh) 2013-03-15 2018-05-01 奈米瑞斯公司 Metadichol*液体和凝胶纳米颗粒制剂
ES2723429T3 (es) * 2014-08-01 2019-08-27 Glenmark Pharmaceuticals Sa Formulación de nanopartículas que comprende un inhibidor de mPGES-1
DK3416684T3 (da) * 2016-02-17 2023-07-31 Regeneron Pharma Fremgangsmåder til behandling eller forebyggelse af atherosklerose ved administration af en hæmmer af ANGPTL3
CN108042507B (zh) * 2017-12-25 2020-06-30 北京颐方生物科技有限公司 一种多廿醇微球及其制备方法与应用
CN114699377B (zh) * 2022-05-18 2023-04-21 湖北中古生物制药有限公司 一种多廿烷醇速释制剂及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6299323A (ja) * 1985-10-25 1987-05-08 Yoshihide Hagiwara 高脂血症剤
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
CU22225A1 (es) * 1990-11-30 1995-01-31 Cent Nac Investig Scient Composicion farmacautica que contiene mezcla de alcoholes alifaticos primarios superiores para el tratamiento de hipercolesterolemia y la hiperlipoproteinemia tipo ii asi como estimulante de la conducta sexual en animales y humanos
CA2221145A1 (en) 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
MXPA02004511A (es) * 1999-11-04 2002-10-11 Monsanto Technology Llc Composiciones de estanol reductoras de colesterol, preparacion y metodo de uso.
US20080241070A1 (en) 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
IT1320180B1 (it) * 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US7214394B2 (en) 2002-05-31 2007-05-08 Archer-Daniels-Midland Company Policosanol compositions, extraction from novel sources, and uses thereof
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
US20070065497A1 (en) 2005-09-20 2007-03-22 Guilford Frederick T Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
WO2004045530A2 (en) 2002-11-15 2004-06-03 The General Hospital Corporation Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors
US20050074443A1 (en) 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
US20050234025A1 (en) 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
US20050267091A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
US20060020043A1 (en) 2004-07-26 2006-01-26 Roger Berlin Methods and compositions for reducing C-reactive protein
US20060020007A1 (en) 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and biotin and their pharmaceutical uses
WO2006135415A2 (en) * 2004-09-08 2006-12-21 University Of Florida Research Foundation, Inc. Micelles and nanoemulsions for preventative and reactive treatment of atherosclerosis
CN101031284A (zh) 2004-09-30 2007-09-05 伊斯曼化学公司 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途
JP2007091672A (ja) * 2005-09-29 2007-04-12 Nof Corp アディポネクチン上昇剤
US8202541B2 (en) * 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
JP5571897B2 (ja) * 2006-02-14 2014-08-13 株式会社ファンケル ビタミンｃトランスポーター産生促進剤
WO2009007785A2 (en) * 2006-11-14 2009-01-15 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
WO2008103926A1 (en) 2007-02-22 2008-08-28 Innlabs, Llc Vitamin c preparation
US20080227747A1 (en) * 2007-03-15 2008-09-18 Tabbiner Philip Composition and methods for treating or preventing degenerative joint and cardiovascular conditions
JP5586381B2 (ja) 2009-10-07 2014-09-10 光洋産業株式会社 ２型糖尿病改善剤及びそれを含有する飲食物

Also Published As

Publication number Publication date
CA2788777A1 (en) 2010-08-26
AU2010216337B2 (en) 2014-07-10
CL2010000063A1 (es) 2011-02-18
EP2398476A1 (en) 2011-12-28
ES2663299T3 (es) 2018-04-11
CN102292088A (zh) 2011-12-21
TW201038287A (en) 2010-11-01
EP2398476B1 (en) 2018-02-07
JP5711671B2 (ja) 2015-05-07
EP2398476A4 (en) 2013-09-11
CA2788777C (en) 2015-02-17
AU2010216337A1 (en) 2011-09-22
US20100215752A1 (en) 2010-08-26
CN102292088B (zh) 2014-01-29
AR075686A1 (es) 2011-04-20
WO2010096231A1 (en) 2010-08-26
US8722093B2 (en) 2014-05-13
JP2012518639A (ja) 2012-08-16

Similar Documents

Publication Publication Date Title
DK2398476T3 (da) Policosanolnanopartikler
US9034383B2 (en) Policosanol nanoparticles
Villar et al. Design and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) for enhanced dissolution of gemfibrozil
Narang et al. Stable drug encapsulation in micelles and microemulsions
Sobel et al. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis
Verma et al. Enhancement in the neuroprotective power of riluzole against cerebral ischemia using a brain targeted drug delivery vehicle
Charkoftaki et al. Novel milk-based oral formulations: proof of concept
FR2730231A1 (fr) Association de fenofibrate et de vitamine e, utilisation en therapeutique
KR20050026705A (ko) 나노입자 피브레이트 제제
Omari-Siaw et al. Hypolipidemic potential of perillaldehyde-loaded self-nanoemulsifying delivery system in high-fat diet induced hyperlipidemic mice: formulation, in vitro and in vivo evaluation
Yamamoto et al. The macrophage and its related cholesterol efflux as a HDL function index in atherosclerosis
Castaño et al. Effects of D-003, a new hypocholesterolaemic and antiplatelet compound, on lipid profile and lipid peroxidation in healthy volunteers
Singhal et al. Preparation, optimization and biological evaluation of gymnemic acid loaded niosomes against streptozotocin-nicotinamide induced diabetic-nephropathy in Wistar rats
Wang et al. Protective role of naringin loaded solid nanoparticles against aflatoxin B1 induced hepatocellular carcinoma
Wang et al. Protective effects of grape seed proanthocyanidin extract in preventing dss induced ulcerative colitis based on pharmacodynamic, pharmacokinetic and tissue distribution
Shimotoyodome et al. Coingestion of acylglycerols differentially affects glucose-induced insulin secretion via glucose-dependent insulinotropic polypeptide in C57BL/6J mice
WO2005055956A2 (en) Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
Wulff-Pérez et al. Preparation, characterization and in vivo evaluation of nanoemulsions for the controlled delivery of the antiobesity agent N-oleoylethanolamine
Chatterjee et al. Improvement of metabolic syndrome by irbesartan via the PPARγ/HGF pathway in apolipoprotein E knockout mice
Ren et al. Supramolecular aggregates of myricetin improve its bioavailability and its role in counteracting alcoholism
Raghavan Policosanol nanoparticles
WO2017120568A1 (en) Apoe mimetic peptide compositions
Singh Polysorbate in biopharmaceuticals—an overview including in vivo fate and safety perspective
Kumar Artesunate loaded self nanoemulsified drug delivery system: a preliminary study for improved efficacy in the treatment of malaria: formulation, characterization and bio-distribution study
Li et al. Assessing the safety of transarterial locoregional delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat liver